Trial Profile
An Open Label Pilot study with oral fludarabine, oral cyclophosphamide and CAMPATH 1H (FCC) for patients with refractory or Relapsed B cells Chronic Lymphocytic Leukaemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2013
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 17 Sep 2013 New trial record